ArticleRadiation oncology (London, England)2016
Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?
Article in Radiation oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Tumor Control Probability Modeling for Radiation Therapy of Keratinocyte Carcinoma.Frontiers in oncology · 2021Pooled it
- Clinical-radiomic model development for local recurrence prediction in stereotactic body radiation therapy-treated lung cancer: comparative analysis with radiobiological models.Scientific reports · 2026Article
- Translational tumor control probability modeling for NSCLC: A two-dimensional maximum-likelihood framework.Medical physics · 2026Article
- Machine learning-based prognostic model for local control prediction in lung cancer patients undergoing stereotactic body radiation therapy: a preliminary study.European journal of medical research · 2026Article
- The Role of PET Image Quantification in Modern Radiation Therapy.PET clinics · 2025Review
- Development and validation of a nomogram for local control prediction in lung cancer patients treated with stereotactic body radiation therapy based on clinical, dosimetric, and inflammation-related parameters.BMC pulmonary medicine · 2025Article
- External validation of radiobiological models for local control prediction in lung cancer patients treated with stereotactic body radiation therapy.Frontiers in oncology · 2024Article
- Article
- Review
- Revisiting the formalism of equivalent uniform dose based on the linear-quadratic and universal survival curve models in high-dose stereotactic body radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS).Journal of applied clinical medical physics · 2021Article
- Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.Journal of Cancer · 2020Review
- Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.Radiation oncology (London, England) · 2019Article
- Dosimetric assessment of tumor control probability in intensity and volumetric modulated radiotherapy plans.The British journal of radiology · 2019Article
- Adaptive hypofractionated gamma knife radiosurgery in the acute management of brainstem metastases.Surgical neurology international · 2019Article
- Comparison of Three Radiobiological Models in Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer.Journal of Cancer · 2019Article
- Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non-small cell lung cancer patients.Experimental and therapeutic medicine · 2018Article
- The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies.Radiation oncology (London, England) · 2018Review
- Comparative Analysis of Local Control Prediction Using Different Biophysical Models for Non-Small Cell Lung Cancer Patients Undergoing Stereotactic Body Radiotherapy.BioMed research international · 2017Article
- Radiobiological Optimization in Lung Stereotactic Body Radiation Therapy: Are We Ready to Apply Radiobiological Models?Frontiers in oncology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the dose-response of stage I non-small-cell lung cancer (NSCLC) in terms of long-term local tumor control (LC) after conventional and hypofractionated photon radiotherapy, modeled with the linear-quadratic (LQ) and linear-quadratic-linear (LQ-L) approaches and to estimate the clinical α/β ratio within the LQ frame. MATERIAL AND
methodsWe identified studies of curative radiotherapy as single treatment through MedLine search reporting 3-year LC as primary outcome of interest. Logistic models coupled with the biologically effective dose (BED) at isocenter and PTV edge according to both the LQ and LQ-L models with α/β = 10 Gy were fitted. Additionally, α/β was estimated from direct LQ fits.
resultsThirty one studies were included reporting outcome of 2319 patients. The LQ-L fit yielded a significant value of 11.0 ± 5.2 Gy for the dose threshold (Dt) for BED10 at the isocenter. The LQ and LQ-L fits did not differ substantially. Concerning the estimation of α/β, the value obtained from the direct LQ fit for the complete fractionation range was 3.9 [68 % CI: 2.2-9.0] Gy (p > 0.05).
conclusionBoth LQ and LQ-L fits can model local tumor control after conventionally and hypofractionated irradiation and are robust methods for predicting clinical effects. The observed dose-effect for local control in NSCLC is weaker at high doses due to data dispersion. For BED10 values of 100-150 Gy in ≥3 fractions, the differences in isoeffects predicted by both models can be neglected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.